Recent advancements in science and technology have addressed physiological hurdles like short gastric residence periods (GRT) and inconsistent stomach emptying times (GET), paving the way for the study and advancement of rate controlled oral drug delivery systems. Numerous efforts have been undertaken to increase patient compliance, therapeutic efficacy, and oral medication bioavailability. To address these needs, numerous controlled-release oral administration devices have been created. When it comes to localized gastric treatment and medications with a limited intestinal solubility and absorption window, The formulation technique of floating dosage forms is of paramount importance. The purpose of the floating- drugs delivery method is to increase bioavailability by extending the duration the stomach remains in one place after oral administration. The necessity to target medications to a particular area of the gastrointestinal tract (GIT), such the stomach, gave rise to the concept of gastric retention. Low density systems known as floating systems have enough buoyancy to pass over gastric contents and stay afloat there for an extended amount of time without slowing down the speed at which the stomach empties. By combining the right components using excipients such as hydrocolloids and inert fatty materials, and buoyancy-enhancing compounds, It is possible to develop floating dosage forms like tablets and capsules. One simple unit dose form that has the advantage of a prolonged drug release duration in the stomach is the floating matrix tablet. For medications with a limited absorption window, reduced stability at high alkaline pH, and improved solubility at low pH, gastro-retentive drugs delivery systems (GRDDS) have become increasingly popular. The goal of this review paper is to provide comprehensive information on the pharmaceutical underpinnings of floating tablet design, classification, benefits and drawbacks, and factors influencing the stomach retitions time of FDDS.